Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $13.00 price target on the stock.
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics Appoints Mert Aktar to its Board of DirectorsPR Newswire
- Kyverna Therapeutics, Inc. (NASDAQ: KYTX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
- Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $16.00 price target on the stock.MarketBeat
- Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024PR Newswire
KYTX
Earnings
- 8/12/24 - Beat
KYTX
Sec Filings
- 10/24/24 - Form 4
- 10/24/24 - Form 3
- 10/21/24 - Form 8-K
- KYTX's page on the SEC website